Trial Profile
A Phase 2, Multicenter, Open-label Study of BGJ398 in Patients With Recurrent Resectable or Unresectable Glioblastoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Apr 2022
Price :
$35
*
At a glance
- Drugs Infigratinib (Primary)
- Indications Glioblastoma; Glioma
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 28 Mar 2022 Primary endpoint (Progression Free Survival) has been met according to the results published in the Clinical Cancer Research
- 28 Mar 2022 Results published in the Clinical Cancer Research
- 13 Sep 2020 This trial has been Discontinued in Italy.